Dextromethorphan Distribution Act of 2007

FDA reform proposals; Pseudoephedrine H.R. 970 DXM Distribution Act S. 1378 DXM Distribution Act S. 2274 Dextromethorphan Abuse Reduction Act Monograph System Reform Proposal S. 2274 DXM Abuse Reduction Act

Client expense: $1,047,210 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Security Agency (NSA), Natl Security Council (NSC), Office of the Vice President of the United States, SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office

Dextromethorphan Abuse, Methampehtamine S. 2237, S. 3374, S. 1378, S 1276, HR 970

Client expense: $65,235 · Firm income: Not reported

Government targets: Consumer Product Safety Commission (CPSC), HOUSE OF REPRESENTATIVES, SENATE

-H.R. 1424, "Paul Wellstone Mental Health and Addiction Equity Act of 2007," regarding amending section 712 of the Employee Retirement Income Security Act of 1974, section 2705 of the Public Health Service Act, and section 9812 of the Internal Revenue Code of 1986 to require equity in the provision of mental health and substance-related disorder benefits under group health plans; -H.R. 1494 / S. 830, "Pediatric Medical Device Safety and Improvement Act of 2007," regarding improving the process for the development of needed pediatric medical devices; -H.R. 1956, "Patient Protection and Innovative Biologic Medicines Act of 2007," regarding amending the public Health Service Act to provide for the approval of similar biological products; -H.R. 2193, "Animal Protection Accountability Improvement Act," regarding amending the Animal Welfare Act to increase the penalties for violations of such Act to prohibit the use of animals for marketing medical devices; -H.R. 2349/ S. 1413, "Uterine Fibroid Research and Education Act of 2007," regarding providing for research and education with respect to uterine fibroids; -H.R. 3333 / S. 1576, "Minority Health Improvement and Health Disparity Elimination Act," regarding amending the Public Health Services Act to improve the health and healthcare of racial and ethnic minority groups; -H.R. 788 / S. 468, "Food and Drug Administration Safety Act of 2007," regarding amending the Federal Food, Drug, and Cosmetic Act with respect to drug safety; -H.R. 2900, "Food and Drug Administration Amendments Act of 2007," regarding amending the Federal Food, Drug, and Cosmetic Act to revise and extend the use-fee programs for prescription drugs and for medical devices and to enhance the postmarket authorities of the Food and Drug Administration with respect to the safety of drugs; -S. 1082, "Food and Drug Administration Revitalization Act," regarding amending the Federal Food, Drug, and Cosmetic Act and the Public Health Service Act to reauthorize drug and device user fees and ensure the safety of medical products; -S. 1695, "Biologics Price Competition and Innovation Act of 2007," regarding amending the Public Health Service Act to establish a pathway for the licensure of biosilimar products to promote innovation in the life sciences; -S. 467, "Fair Access to Clinical Trials Act of 2007 or the 'FACT Act'," regarding amending the Public Health Services Act to expand clinical trials drug data bank; -S. 558, "Mental Health Parity Act of 2007," regarding all provisions ; -S. 628, "Critical Access to Health Information Technology Act of 2007," regarding improving grants for rural health information technology development activities; -S. 993, "Pediatric Research Improvement Act," regarding improving pediatric research; issues regarding Acetemorphine and Phenelyperine; -H.R. 3580, "Food and Drug Administration Amendments Act of 2007," regarding fees related to prescription drugs, medical devices, and food safety; -H.R. 2419 / S. 2302, "Food and Energy Security Act of 2007," regarding marketing and financial assistance related to farming and food production; -H.R. 5606 / S. 2029, "Physician Payments Sunshine Act of 2007," regarding amending Title XI of the Social Security Act to provide for transparency in the relationship between physicians and manufacturers of drugs, devices, or medical supplies for which payment is made under Medicare, Medicaid, or SCHIP; -S. 2221, "Transparency in Medical Device Pricing Act of 2007," regarding amending Title XVIII of the Social Security Act to provide for the reporting of sales price data for implantable devices; -H.R. 3043, "Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2008," regarding appropriations for the Department of Health and Human Services; -H.R. 5629, "Pathway for Biosimilar Act," regarding amending the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products; -H.R. 5839, "Safeguarding America's Pharmaceuticals Act of 2008", To Amend the Federal Food, Drug, and Cosmetic Act to improve the safety of drugs, regarding all provisions; -S. 334, "Healthy Americans Act", A bill to provide affordable, guaranteed private health coverage that will make Americans healthier and can never be taken away, regarding all provisions; -H.R. 6381, "Medical Device Safety Act of 2008", To amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices, regarding all provisions; -S. 438, "Fair Prescription Drug Competition Act", A bill to amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs, regarding all provisions; -S.2274, "A bill to amend the Controlled Substances Act to prevent the abuse of dextromethorphan", and for other purposes, regarding all provisions. -S.3409 "A bill to amend the Federal Food, Drug, and Cosmetic Act to ensure the safety and quality of medical products and enhance the authorities of the Food and Drug Administration", and for other purposes; regarding all provisions. -S.1378 "A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to the distribution of the drug dextromethorphan", and for other purposes; regarding all provisions. -S. 3408, "Comparative Effectiveness Research Act of 2008", A bill to amend title XI of the Social Security Act to provide for the conduct of comparative effectiveness research and to amend the Internal Revenue Code of 1986 to establish a Comparative Effectiveness Research Trust Fund, and for other purposes, regarding all provisions; -S. 1276, "Methamphetamine Production Prevention Act of 2008", A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices, regarding all provisions. -Proposed Rule (CMS-1403-P), Regarding revisions to Amendment of the E-Prescribing Exemption for Computer Generated Facsimile Transmissions; -S.2424, "A bill to ensure that all Americans have basic health literacy skills to function effectively as patients and health care consumers", regarding all provisions.

Client expense: $1,440,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

-S. 635, "Methamphetamine Remediation Research Act of 2007," regarding providing for a research program for remediation of closed methamphetamine production laboratories; issues regarding Federal judicial salaries; -S. 2274, "Dextromethorphan Abuse Reduction Act of 2007", A bill to amend the Controlled Substances Act to prevent the abuse of dextromethorphan, and for other purposes, regarding all provisions; -S. 1378, "Dextromethorphan Distribution Act of 2007", A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to the distribution of the drug dextromethorphan, and for other purposes; -S. 1276, "Methamphetamine Production Prevention Act of 2008 ", A bill to establish a grant program to facilitate the creation of methamphetamine precursor electronic logbook systems, and for other purposes, regarding all provisions. -S.2071, "A bill to enhance the ability to combat methamphetamine", regarding all provisions.

Client expense: $1,440,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 970/S. 1378 To amend the Federal Food, Drug and Cosmetic Act with respect to the distribution of the drug Dextromethorphan, and for other purposes; (Sections pertaining to DXM.)

Client expense: $1,970,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 4703, S 2467, HR 4991 - Vaccine Shortage preparedness Act of 2008 S 2464, HR 4992, HR 4704 - A bill to amend title XVIII of the Social Security Act to provide for coverage of federally recommended vaccines under Medicare Part B S 2465 - Vaccines for Children Access Act of 2008 HR 5839 - Safeguarding America's Pharmaceuticals Act of 2008 S 3408 - Comparative Effectiveness Research Act of 2008 HR 4702, HR 4990 - A bill to amend title XIX of the Social Security Act to include all public clinics for the distribution of pediatric vaccines under the Medicaid program. HR 4705 HR 4993, S 2466 - Vaccines for the uninsured Adult Act of 2008 S 2467 - Vaccine shortage preparedness Act of 2008 S 3678 - /PL 109-417 All pandemic and all-hazards act - Section 317 program issues HR 970 and S 1378 - Dextromethorphan Distribution Act of 2007 S 103 - Combat Meth Act of 2005 HR 2207 - Agricultural Disaster Assistance and Western States Emergency - Unfinished business Appropriations Act of 2007 HR 1908 and S 1710 Patent Reform Act of 2007 HR 1 - Implementing the 9/11 Commission recommendations Act of 2007 HR 3162 - Children's Health and Medicare Protection Act of 2007 S 1505 - Affordable Biologics for Consumers Act S 1695 - Biologics Price Competition and Innovation Act of 2007 HR 1956 - Patent Protection and Innovative Biologic Medicines Act of 2007 HR 1038, S623 - Access to Life-Saving Medicine Act HR 4083 - Non-prescription Drug Modernization Act of 2007 HR 1308 - Legal Immigrant Children's Health Improvement Act of 2007 HR 5629 - Pathway for Biosimilars Act Comparative Effectiveness Research Public Health Service Act Drug Importation Gene Therapy Direct to Consumer Advertising Drug Safety Legislation Global Hypertension

Client expense: $1,340,838 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, U.S. Agency for International Development (USAID)

S 1378/HR 970, Dextromethorphan Distribution Act of 2007, restrictions on distribution of bulk Dextromethorphan.

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 130, HR 146, HR 258, HR 688, HR 880, HR 980, HR 1118, HR 1694, HR 1700, HR 1890, HR 1895, HR 2542, HR 2664, HR 2726, HR 2797, HR 2979, HR 3153, HR 3546, HR 3547, HR 5180, HR 5516, HR 6045, S 47, S 77, S144, S 345, S 368, S 376, S 393, S 456, S 1378, S 2123, S 2237, S 2511, S 2565 and other matters relating to the wages, hours. and working conditions of public safety officers.

Client expense: $20,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), SENATE

FDA reform proposals; Pseudoephedrine H.R. 970 DXM Distribution Act S. 1378 DXM Distribution Act S. 2274 Dextromethorphan Abuse Reduction Act Monograph System Reform Proposal S. 2274 DXM Abuse Reduction Act

Client expense: $756,650 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Security Agency (NSA), Natl Security Council (NSC), Office of the Vice President of the United States, SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office

H.R. 970/S. 1378 To amend the Federal Food, Drug and Cosmetic Act with respect to the distribution of the drug Dextromethorphan, and for other purposes; (Sections pertaining to DXM.)

Client expense: $1,591,930 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

-S. 635, "Methamphetamine Remediation Research Act of 2007," regarding providing for a research program for remediation of closed methamphetamine production laboratories; issues regarding Federal judicial salaries; -S. 2274, "Dextromethorphan Abuse Reduction Act of 2007", A bill to amend the Controlled Substances Act to prevent the abuse of dextromethorphan, and for other purposes, regarding all provisions; -S. 1378, "Dextromethorphan Distribution Act of 2007", A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to the distribution of the drug dextromethorphan, and for other purposes; -S. 1276, "Methamphetamine Production Prevention Act of 2008 ", A bill to establish a grant program to facilitate the creation of methamphetamine precursor electronic logbook systems, and for other purposes, regarding all provisions.

Client expense: $1,500,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

HR 4703, S 2467, HR 4991 - Vaccine Shortage preparedness Act of 2008 S 2464, HR 4992, HR 4704 - A bill to amend title XVIII of the Social Security Act to provide for coverage of federally recommended vaccines under Medicare Part B S 2465 - Vaccines for Children Access Act of 2008 HR 5839 - Safeguarding America's Pharmaceuticals Act of 2008 S 3408 - Comparative Effectiveness Research Act of 2008 HR 4702, HR 4990 - A bill to amend title XIX of the Social Security Act to include all public clinics for the distribution of pediatric vaccines under the Medicaid program. HR 4705 HR 4993, S 2466 - Vaccines for the uninsured Adult Act of 2008 S 2467 - Vaccine shortage preparedness Act of 2008 S 3678 - /PL 109-417 All pandemic and all-hazards act - Section 317 program issues HR 970 and S 1378 - Dextromethorphan Distribution Act of 2007 S 103 - Combat Meth Act of 2005 HR 2207 - Agricultural Disaster Assistance and Western States Emergency - Unfinished business Appropriations Act of 2007 HR 1908 and S 1710 Patent Reform Act of 2007 HR 1 - Implementing the 9/11 Commission recommendations Act of 2007 HR 3162 - Children's Health and Medicare Protection Act of 2007 S 1505 - Affordable Biologics for Consumers Act S 1695 - Biologics Price Competition and Innovation Act of 2007 HR 1956 - Patent Protection and Innovative Biologic Medicines Act of 2007 HR 1038, S623 - Access to Life-Saving Medicine Act HR 4083 - Non-prescription Drug Modernization Act of 2007 HR 1308 - Legal Immigrant Children's Health Improvement Act of 2007 HR 5629 - Pathway for Biosimilars Act Comparative Effectiveness Research Public Health Service Act Drug Importation Gene Therapy Direct to Consumer Advertising Drug Safety Legislation Global Hypertension

Client expense: $1,377,211 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, U.S. Agency for International Development (USAID)

Dextromethorphan Abuse, Methamphetamine S. 2237, S. 2274, S. 1378, HR 970, S. 1276

Client expense: $116,217 · Firm income: Not reported

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE

S 1378/HR 970, Dextromethorphan Distribution Act of 2007, restrictions on distribution of bulk Dextromethorphan.

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 130, HR 146, HR 258, HR 688, HR 880, HR 980, HR 1118, HR 1694, HR 1700, HR 1890, HR 1895, HR 2542, HR 2664, HR 2726, HR 2797, HR 2979, HR 3153, HR 3546, HR 3547, HR 5180, HR 5516, HR 6045, S 47, S 77, S144, S 345, S 368, S 376, S 393, S 456, S 1378, S 2123, S 2237, S 2511, S 2565 and other matters relating to the wages, hours. and working conditions of public safety officers.

Client expense: $20,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), SENATE

Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.

Client expense: Not reported · Firm income: Not reported

Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.

Client expense: Not reported · Firm income: Not reported

Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.

Client expense: Not reported · Firm income: Not reported

Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.

Client expense: Not reported · Firm income: Not reported

Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.

Client expense: Not reported · Firm income: Not reported

Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.

Client expense: Not reported · Firm income: Not reported

Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.

Client expense: Not reported · Firm income: Not reported

Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.

Client expense: Not reported · Firm income: Not reported

Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.

Client expense: Not reported · Firm income: Not reported

FDA reform proposals; Pseudoephedrine H.R. 970 DXM Distribution Act S. 1378 DXM Distribution Act S. 2274 Dextromethorpha Abuse Reduction Act Monograph System Reform Proposal S. 2274 DXM Abuse Reduction Act

Client expense: $801,472 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Security Agency (NSA), Natl Security Council (NSC), Office of the Vice President of the United States, SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office

Dextromethorphan Abuse S. 2237, S. 2274, S. 1378, H.R. 970

Client expense: $110,000 · Firm income: Not reported

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE

Dextromethorphan Abuse, Methamphetamine S. 2237, S. 2274, S. 1378, H.R. 970, S. 1276

Client expense: $150,000 · Firm income: Not reported

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE

HR 4703, S 2467, HR 4991 - Vaccine Shortage preparedness Act of 2008 S 2464, HR 4992, HR 4704 - A bill to amend title XVIII of the Social Security Act to provide for coverage of federally recommended vaccines under Medicare Part B S 2465 - Vaccines for Children Access Act of 2008 HR 4702, HR 4990 - A bill to amend title XIX of the Social Security Act to include all public clinics for the distribution of pediatric vaccines under the Medicaid program. HR 4705 HR 4993, S 2466 - Vaccines for the uninsured Adult Act of 2008 S 2467 - Vaccine shortage preparedness Act of 2008 S 3678 - /PL 109-417 All pandemic and all-hazards act - Section 317 program issues HR 970 and S 1378 - Dextromethorphan Distribution Act of 2007 S 103 Combat Meth Act of 2005 HR 2207 - Agricultural Disaster Assistance and Western States Emergency - Unfinished business Appropriations Act of 2007 HR 1908 and S 1710 Patent Reform Act of 2007 HR 1 - Implementing the 9/11 Commission recommendations Act of 2007 HR 3162 - Children's Health and Medicare Protection Act of 2007 S 1505 Affordable Biologics for Consumers Act S 1695 Biologics Price Competition and Innovation Act of 2007 HR 1956 - Patent Protection and Innovative Biologic Medicines Act of 2007 HR 1038, S623 - Access to Life-Saving Medicine Act HR 4083 - Non-prescription Drug Modernization Act of 2007 HR 1308 - Legal Immigrant Children's Health Improvement Act of 2007 HR 5629 - Pathway for Biosimilars Act Comparative Effectiveness Research Public Health Service Act Drug Importation Gene Therapy Direct to Consumer Advertising Drug Safety Legislation Global Hypertension

Client expense: $1,345,921 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, U.S. Agency for International Development (USAID)

S. 635, "Methamphetamine Remediation Research Act of 2007," regarding providing for a research program for remediation of closed methamphetamine production laboratories; issues regarding Federal judicial salaries; S. 2274, "A bill to amed the Controlled Substances Act to prevent the abuse of dextromethorphan, and for other purposes", regarding all provisions; S. 1378, "A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to the distribution of the drug dextromethorphan, and for other purposes; S. 1276, "A bill to establish a grant program to facilitate the creation of methamphetamine precursor electronic logbook systems, and for other purposes", regarding all provisions.

Client expense: $1,700,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

S 1378/HR 970, Dextromethorphan Distribution Act of 2007, restrictions on distribution of bulk Dextromethorphan.

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 4703, S. 2467, H.R. 4991 -- Vaccine Shortage Preparedness Act of 2008 S. 2467, H.R. 4703, H.R. 4991 -- A bill to amend the Social Security Act, the Federal Food, Drug and Cosmetic Act, and the Public Health Service Act H.R. 970 and S. 1378 -- Dextromethorphan Distribution Act S. 3678 -- Pandemic All Hazards Preparedness Act (Biodefense) S. 103 Combat Meth Act H.R. 1908 and S. 1710 -- Patient Reform Act H.R. 3162 -- Children's Health and Medicare Protection Act S. 1505 -- Affordable Biologics for Consumers Act S. 1695 -- Biolgoics Price Competition and Innovation Act Comparative effectiveness research Drug importation Direct to consumer advertising Drug safety legislation FDA funding Issues related to the use of thimerisol in vaccines

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 130, HR 146, HR 258, HR 688, HR 880, HR 980, HR 1118, HR 1694, HR 1700, HR 1890, HR 1895, HR 2542, HR 2664, HR 2726, HR 2797, HR 2979, HR 3153, HR 3546, HR 3547, HR 5180, HR 5516, HR 6045, S 47, S 77, S144, S 345, S 368, S 376, S 393, S 456, S 1378, S 2123, S 2237, S 2511, S 2565 and other matters relating to the wages, hours. and working conditions of public safety officers.

Client expense: $20,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), SENATE

HR 130, HR 146, HR 258, HR 688, HR 880, HR 980, HR 1118, HR 1694, HR 1700, HR 1890, HR 1895, HR 2542, HR 2664, HR 2726, HR 2797, HR 2979, HR 3153, HR 3546, HR 3547, HR 5180, HR 5516, HR 6045, S 47, S 77, S144, S 345, S 368, S 376, S 393, S 456, S 1378, S 2123, S 2237, S 2511, S 2565 and other matters relating to the wages, hours. and working conditions of public safety officers.

Client expense: $20,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), SENATE

FDA reform proposals; Pseudoephedrine S. 1276 Methamphetamine Production Preventation Act of 2007 H.R. 970 DXM Distribution Act S. 1378 DXM Distribution Act DXM Abuse Monograph System Reform Proposal S. 2274 DXM Abuse Reduction Act H.R. 4083 Non-Prescription Drug modernization Act of 2007

Client expense: $697,236 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Security Agency (NSA), Natl Security Council (NSC), Office of the Vice President of the United States, SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office

HR4703, S2467, HR4991 - Vaccine Shortage Preparedness Act of 2008 S2464, HR4992, HR4704 - A bill to amend title XVIII of the Social Security Act to provide for coverage of federally recommended vaccines under Medicare part B S. 2465, HR 4702, HR 4990 A bill to amend title XIX of the Social Security Act to include all public clinics for the distribution of pediatric vaccines under the Medicaid program. S. 2467, HR 4703, HR 4991 A bill to amend the Social Security Act, the Federal Food, Drug and Cosmetic Act, and the Public Health Service Act to ensure a sufficient supply of vaccines, and for other purposes. HR4705 - Vaccines for the Uninsured Adult Act of 2008 S3678 H.R. 970 and S. 1378 - Dextromethorphan Distribution Act of 2007 S.3678 Pandemic All Hazards Preparedness Act (Biodefense) S.103 Combat Meth Act of 2005 H.R. 2207 - Agricultural Disaster Assistance and Western States Emergency Unfinished Business Appropriations Act of 2007 H.R. 1908 and S. 1710 - Patent Reform Act of 2007 H.R 1 - Implementing the 9/11 Commission Recommendations Act of 2007 H.R. 3162 - Children's Health and Medicare Protection Act of 2007 S. 1505 Affordable Biologics for Consumers Act S. 1695 Biologics Price Competition and Innovation Act of 2007 H.R. 1956 Patient Protection and Innovative Biologic Medicines Act of 2007 H.R. 1038 Access to Life-Saving Medicine Act S.623 Access to Life-Saving Medicine Act H.R. 4083 Non-Prescription Drug Modernization Act of 2007 S. 2311 Non-Prescription Drug Modernization Act of 2007 Comparative Effectiveness Research Public Health Service Act Drug Importation Gene Therapy Direct to Consumer Advertising Drug Safety Legislation Global Hypertension Best Pharmaceuticals for Children's Act Pediatric Research Equity Act Pharmaceuticals in water FDA Funding Reagan/Udall Foundation Counter Detailing

Client expense: $1,250,450 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, U.S. Agency for International Development (USAID)

Dextromethorphan Abuse S. 2237, S. 2274, S. 1378, H.R. 970

Client expense: $110,000 · Firm income: Not reported

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE

H.R. 4703, S. 2467, HR 4991 -- Vaccine Shortage Preparedness Act of 2008 S 2467, HR 4703, HR 4991 -- A bill to amend the Social Security Act, the Federal Food, Drug and Cosmetic Act, and the Public Health Service Act HR 970 and S 1378 -- Dextromethorphan Distribution Act of 2007 S 3678 -- Pandemic All Hazards Preparedness Act (Biodefense) S 103 Combat Meth Act of 2005 HR 1908 -- and S 1710 -- Patent Reform Act of 2007 HR 3162 -- Children's Health and Medicare Protection Act of 2007 S 1505 -- Affordable Biologics for Consumers Act S 1695 Biologics Price Competition and Innovation Act of 2007 Comparative effectiveness research Drug importation Direct to consumer advertising Drug safety legislation FDA funding Issues related to the use of thimerisol in vaccines

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 4703, S. 2467, HR 4991 -- Vaccine Shortage Preparedness Act of 2008 S 2467, HR 4703, HR 4991 -- A bill to amend the Social Security Act, the Federal Food, Drug and Cosmetic Act, and the Public Health Service Act HR 970 and S 1378 -- Dextromethorphan Distribution Act of 2007 S 3678 -- Pandemic All Hazards Preparedness Act (Biodefense) S 103 Combat Meth Act of 2005 HR 1908 -- and S 1710 -- Patent Reform Act of 2007 HR 3162 -- Children's Health and Medicare Protection Act of 2007 S 1505 -- Affordable Biologics for Consumers Act S 1695 Biologics Price Competition and Innovation Act of 2007 Comparative effectiveness research Drug importation Direct to consumer advertising Drug safety legislation FDA funding Issues related to the use of thimerisol in vaccines

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S 1378/HR 970, Dextromethorphan Distribution Act of 2007, restrictions on distribution of bulk Dextromethorphan.

Client expense: Not reported · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S.2274, S.1378, H.R.970; Seeking increased restrictions on sale of Dextromethorphan, including prohibition of internet sale of bulk Dextromethorphan and under age 18 restrictions.

Client expense: Not reported · Firm income: Not reported

S.2274, S.1378, H.R.970; Seeking increased restrictions on sale of Dextromethorphan, including prohibition of internet sale of bulk Dextromethorphan and under age 18 restrictions.

Client expense: Not reported · Firm income: Not reported

S. 1378 and HR 970 - Dextromethorphan Distribution Act of 2007 - Restrictions on distribution of bulk Dextromethorphan.

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Delays in HIPPA required NPI registery Docket No. 2007N-0356 Comments and Statement Submitted on Behind the Counter Availability of Certain Drugs RE: Docket No. CMS-1385-FC. 42 CFR Parts.160. Medicare Program: Amendment if the E-Prescribing Exemption for Computer-Generated Facsimiles Docket No. 2007P-0074 Joint Meeting of the Nonprescription Drugs Advisory Committee and Pediatric Advisory Committee -Cough and Cold Medications use in Children Statements Submitted on the FDA Nonprescription Drugs Advisory Committee and the Endodrinologic and Metabolic Drugs Advisory Committee Over-the-Counter Use of Mevacor (lovastatin) Voluntary Restricted Distribution of 40mg Methadone to Hospitals Statements Submitted to Senate Judiciary Committee on "Electronic Prescribing of Controlled Substances: Addressing Health Care and Law Enforcement Proirities" Docket No. DEA 298 Combat Methamphetamine Epidemic Act 2005 Self-Certification S1276 Methamphetamine Production Prevention Act of 2007 HR 2747 Methamphetamine Production Prevention Act of 2007 HR 3580 Food and Drug Administration Amendments Act of 2007 HR 2900 Food and Drug Administration Amendments Act of 2007 S 1378 Dextromethorphan Distribution Act of 2007 HR 970 Dextromethorphan Distribution Act of 2007 S 1695 Biologics Price Competition and Innovation Act of 2007

Client expense: $367,997 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE, UNDETERMINED

H.R. 970 and S. 1378 - Dextromethorphan Distribution Act of 2007 S.3678 Pandemic All Hazards Preparedness Act (Biodefense) S.103 Combat Meth Act of 2005 H.R. 2206 - Suplemental Appropriations

Client expense: $3,460,000 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, U.S. Agency for International Development (USAID)

HR 970, S 1378, S 2237, S 2274 -- Medicine Abuse

Client expense: $244,322 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE